Understand the risk of euglycemic DKA with use of sodium glucose co-transporter 2 inhibitors in an inpatient setting.
Describe the prevalence of euglyecmia DKA among patients with inpatient hospital admissions with prior or active sodium glucose co-transporter 2 therapy.
Utilize clinical decision support approaches to prompt for potential euglycemic DKA evaluation in an inpatient setting.
